IL17RB expression might predict prognosis and benefit from gemcitabine in patients with resectable pancreatic cancer.
Pathology - Research and Practice（2019）
摘要
IL17RB predicts the prognosis and benefit from gemcitabine in patients with resectable pancreatic cancer.
更多查看译文
关键词
Pancreatic cancer,IL17RB,Immunohistochemistry,Biomarker
AI 理解论文
溯源树
样例
生成溯源树，研究论文发展脉络
Chat Paper
正在生成论文摘要